Neuroendocrine carcinoma drug granted orphan status
Drug Discovery World
AUGUST 20, 2024
PT217 was granted ODD for the treatment of SCLC by the FDA in 2022 and granted Fast Track designation by the agency in 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
Let's personalize your content